ABSTRACT
Objectives To explore the experiences of bereaved family of anticipatory (JIC) injectable medications for symptom management and to identify ways to improve practice.
Methods A single site, mixed methods study in two phases. A postal questionnaire sent to 100 family carers (FCs) achieved a 38% response rate of whom 79% volunteered for an interview and 14 were sampled to reflect use of medication, concerns and relationship with the deceased.
The descriptively analysed quantitative data and thematically analysed qualitative data were triangulated
Results The vast majority (89%) perceived benefits to JIC medications but 18% of these described mixed feelings and issues, related to the context of dying and the responsibility for powerful medications. Communication was a key theme and some FCs described emotional impacts, misinterpretation of the intent of the medications and many desired more information to equip and empower them. There were diverse experiences of obtaining medications and guidance on storage and disposal resulting in distressing experiences.
Whilst most described good experiences of care and effectiveness of treatment 50% experienced delay in attendance of staff to administer medication. The majority of those interviewed would have been prepared to administer injections and the key driver for this was their experience of delays in resolving symptoms.
Conclusions FCs were generally positive about JIC medicines and care received but they had also been a source of distress and anxiety and people wanted more information and empowerment. Professional support had often been difficult to access at the point at which it had been needed.
Key Messages
What was already known?
Anticipatory medications for symptom management in the last days of life are promoted as good practice by NICE
Health professionals support this but have identified complexities and concerns
There is no research exploring family or patient views and experiences
What are the new findings?
Family thought there were benefits but frequently described distressing experiences
Delay in support to administer medications was common
With appropriate supervision some family care givers would consider administration
What is their significance?
Just-in-case medications are a trigger for thinking about dying. Practitioners need to anticipate that family may:
Realise for the first time that their loved one is going to die
Think that they are dying now, or more ill than previously suggested
Think these drugs actually end life.
Family need more guidance about looking after a sick/dying person
A PROM related to ‘time to attend’ should be considered.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Part funding for the project was awarded by the Mason Medical Research Trust for APi and APa. Funding for CF, KM and HH was provided by their employing organisation LOROS Hospice, Leicester. The NIHR East Midlands Clinical Research Network funded time for research nurses and administrator time. None of the funders had a role in the study design, analysis or interpretation of the data
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A favourable ethical opinion was given by the Leicester South Research Ethics committee in May 2019 ref 19/EM/0049. Informed by the study information sheets, participants gave consent to the use of their anonymised data in the research and in publications through return of the questionnaire and through formal signed consent for those participating in an interview.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
authorship list and organisation of lead author
Data Availability
All data produced in the present study are available upon reasonable request to the authors
